Oncopharmpod
MARIPOSA
- Author: Vários
- Narrator: Vários
- Publisher: Podcast
- Duration: 0:10:20
- More information
Informações:
Synopsis
The MARIPOSA study suggests there may be a new preferred first line regimen (amivantamab + lazertinib) for metastatic EGFR-mutated NSCLC, as this regimen improved PFS compared to osimertinib.
